Year: 2025

Vancouver, BC, Nov. 03, 2025 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF). At the request of CIRO, the Company wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity. Humanoid Global is a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, it has a current advertising program that was announced on October 31, 2025. This news release may contain assumptions, estimates, and other forward-looking statements regarding future events. Such forward-looking statements involve inherent risks and uncertainties and are subject to factors, many of...

Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that it will present two oral presentations and seven poster presentations on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for multiple myeloma at the 67th Annual American Society of Hematology (ASH) Annual Meeting taking place from December 6-9, 2025, in Orlando, FL. In addition to the CARVYKTI data, the Company will also deliver an oral presentation on Lucar-G39D, its investigational and novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being evaluated...

Information on share capital and voting rights October 2025 Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations. November 3rd, 2025 Statement made by:         Nexans S.A.Registered office : 4 Allée de l’Arche – 92400 CourbevoieRCS Nanterre 393 525 852Regulated market of Euronext Paris (Compartment A)DateTotal number of sharesTotal number of voting rightsTheorical (1) Exercisable (2)October 31st, 2025 43,744,779 43,744,779 43,737,270(1)   Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations). (2)    For information, excluding treasury shares stripped of voting rights, excluding liquidity contract. Provision of Nexans articles of association...

Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapy NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Oslo, 3 November 2025: Zelluna ASA (“Zelluna” or the “Company”), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer contemplates a private placement of NOK 50-55 million in gross proceeds and a retail offering of new shares through PrimaryBid raising gross...

Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its third quarter 2025 results today. Webcast scheduled for 4 November 2025, at 09:00 (CET). Link to webcast here. Third Quarter 2025 Business Update HighlightsPositive MHRA feedback and strengthened clinical strategy supporting UK clinical developmentIn October 2025 (post period announcement), Zelluna announced it had received positive scientific advice from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). The feedback provided alignment across the preclinical, manufacturing, clinical, and regulatory strategy for ZI-MA4-1 and supports the planned Clinical Trial Application (CTA) submission later this year,...

PRESS RELEASE Wolters Kluwer shareholders approve appointment ofMs. Rose Lee and Mr. Hikmet Ersek to the Supervisory Board Alphen aan den Rijn, The Netherlands — November 3, 2025 — Wolters Kluwer announces that Ms. Rose Lee and Mr. Hikmet Ersek have been appointed as Members of the Supervisory Board by an Extraordinary General Meeting of Shareholders (“EGM”) held today. The appointments are effective immediately and are for the period starting November 3, 2025, and ending after the AGM to be held in 2030. Both candidates are seasoned executives with extensive managerial and Board experience in complex industries. Their appointment will further strengthen the Supervisory Board’s ability to oversee and support the company’s strategic direction aimed at long-term value creation. Ms. Lee is former CEO and Board member of Cornerstone Building...

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it is sponsoring the Dream Bowl 2026 and set a record date of November 14, 2025 for its shareholders to receive Dream Bowl 2026 Meme Coin, which will be distributed by DataVault AI. Scilex’s shareholders as of the record date of November 14, 2025 will receive one meme coin for each common share held. This digital collectible is intended to provide for immutable recognition of ownership and utility with ticketing information and embed exclusive details on invited athletes,...